新辅助治疗评分预测临床Ⅲ期中低位直肠癌预后研究

摘要

Objective To investigate the effects of downstaging and neoadjuvant reetal(NAR) score on the prognosis of patients with clinical stage Ⅲ middle-low rectal cancer undergoing preoperative concurrent chemoradiotherapy.Methods From 2006 to 2014,195 patients who were admitted to our hospital and diagnosed with clinical stage Ⅲ middle-low rectal cancer by pelvic magnetic resonance imaging or computed tomography were enrolled.All patients received preoperative radiotherapy with doses of 42-50.4 Gy (median:50 Gy,93.8％ of patients received doses of ≥ 50 Gy) and concurrent chemotherapy with capecitabine ± oxaliplatin.Total mesorectal (R0) excision surgery was performed at 4-15 weeks (median:7 weeks) after concurrent chemoradiotherapy.The effects of downstaging (stage yp0-Ⅱ) and NAR score (calculated based on cT staging and ypT/N staging) on the prognosis were evaluated.The 3-year disease-free survival (DFS) rate was calculated using the Kaplan-Meier method and analyzed by log-rank test.Results In all the patients,the median follow-up time was 44 months (6.7-125.5 months);the 3-year DFS rate was 76.8％.Downstaging after preoperative chemoradiotherapy was a significant prognostic factor for the 3-year DFS (92.2％ vs.56.8％,P=0.000).The median NAR score was 15.0(0-65.0) in all the patients.Patients with NAR scores of ≤ 15.0 had significantly improved 3-year DFS than those with NAR scores of＞15.0(90.1％ vs.57.0％,P=0.001).In patients with downstaging,those with NAR scores of ≤8.4 had significantly improved prognosis compared with those with NAR scores of＞ 8.4(95.1％ vs.87.5％,P=0.022).Conclusions Patients with downstaging after preoperative concurrent chemoradiotherapy for stage c Ⅲ middle-low rectal cancer have satisfactory prognosis.The NAR score is an effective prognostic predictor.%目的 探讨临床Ⅲ期中低位直肠癌经术前同步放化疗后降期以及新辅助治疗评分(NAR)对预后的影响.方法 分析2006-2014年间本中心收治的经盆腔核磁或腹盆CT确诊的cⅢ期中低位直肠癌195例患者,术前放疗42.0～ 50.4 Gy(中位数50 Gy,93.8％患者放疗剂量≥50 Gy),卡培他滨±奥沙利铂同步化疗于同步放化疗后4-15周(中位数7周)TME手术(Ro切除).分析患者降期(yp0-Ⅱ期)及NAR评分(根据cT、ypT/N分期计算)对预后影响,应用Kaplan-Meier法计算3年DFS并Logrank法检验.结果 全组患者中位随访44个月(6.7～ 125.5个月),3年DFS为76.8％.术前同步放化疗后降期显著影响3年DFS (92.2％∶56.8％,P=0.000).全组患者中位NAR评分15.0分(0～65.0分),其中评分低者3年DFS优于评分高者[≤15.0分(90.1％)∶＞15.0分(57.0％),P=0.001];在降期患者中低NAR评分仍可获得更好的预后[≤8.4分(95.1％)∶＞8.4分(87.5％),P=0.022].结论 cⅢ期中低位直肠癌经术前同步放化疗后降期者预后相对较好,NAR评分可有效预测患者预后.